MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 414078 | Name: Eserine salicylate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Eserine salicylate is used to treat anticholinergic poisoning (that is, poisoning by substances that interfere with the transmission of acetylcholine signaling, such as atropine, scopolamine, and other anticholinergic drug overdoses). It contains these two cpds; reverses diazepam-induced sleep.

Chemical Structure

Eserine salicylate
Eserine salicylate
CAS#71214-04-5

Theoretical Analysis

MedKoo Cat#: 414078

Name: Eserine salicylate

CAS#: 71214-04-5

Chemical Formula: C29H36N3NaO9S

Exact Mass: 625.2070

Molecular Weight: 625.67

Elemental Analysis: C, 55.67; H, 5.80; N, 6.72; Na, 3.67; O, 23.01; S, 5.12

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Eserine salicylate; Antilirium
IUPAC/Chemical Name
Benzoic acid, 2-hydroxy-, compd. with (3aS-cis)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-yl methylcarbamate (1:1), mixt. with benzenemethanol and sodium hydrogen sulfite
InChi Key
PECXBGSMLZZDQM-DSXCFSFJSA-M
InChi Code
InChI=1S/C15H21N3O2.C7H6O3.C7H8O.Na.H2O3S/c1-4-16-14(19)20-10-5-6-12-11(9-10)15(2)7-8-17-13(15)18(12)3;8-6-4-2-1-3-5(6)7(9)10;8-6-7-4-2-1-3-5-7;;1-4(2)3/h5-6,9,13,17H,4,7-8H2,1-3H3,(H,16,19);1-4,8H,(H,9,10);1-5,8H,6H2;;(H2,1,2,3)/q;;;+1;/p-1/t13-,15+;;;;/m1..../s1
SMILES Code
CCNC(Oc1cc2c(N([C@H]3NCC[C@]32C)C)cc1)=O.OCc4ccccc4.OC(c5c(O)cccc5)=O.OS([O-])=O.[Na+]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 625.67 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Hoffman RJ, Nelson LS, Hoffman RS. Use of ferric chloride to identify salicylate-containing poisons. J Toxicol Clin Toxicol. 2002;40(5):547-9. doi: 10.1081/clt-120014643. PMID: 12215048. 2: Daunderer M. Physostigmine salicylate as an antidote. Int J Clin Pharmacol Ther Toxicol. 1980 Dec;18(12):523-35. PMID: 7228447. 3: MEDAKOVIC M, VARAGIC V. The effect of eserine and neostigmine on the blood pressure of conscious rats. Br J Pharmacol Chemother. 1957 Mar;12(1):24-7. doi: 10.1111/j.1476-5381.1957.tb01356.x. PMID: 13413146; PMCID: PMC1509647. 4: Pinder N, Bruckner T, Lehmann M, Motsch J, Brenner T, Larmann J, Knebel P, Hoppe-Tichy T, Swoboda S, Weigand MA, Hofer S, Zimmermann JB. Effect of physostigmine on recovery from septic shock following intra-abdominal infection - Results from a randomized, double-blind, placebo-controlled, monocentric pilot trial (Anticholium® per Se). J Crit Care. 2019 Aug;52:126-135. doi: 10.1016/j.jcrc.2019.04.012. Epub 2019 Apr 9. PMID: 31035187. 5: Zimmermann JB, Pinder N, Bruckner T, Lehmann M, Motsch J, Brenner T, Hoppe- Tichy T, Swoboda S, Weigand MA, Hofer S. Adjunctive use of physostigmine salicylate (Anticholium®) in perioperative sepsis and septic shock: study protocol for a randomized, double-blind, placebo-controlled, monocentric trial (Anticholium® per Se). Trials. 2017 Nov 10;18(1):530. doi: 10.1186/s13063-017-2231-x. PMID: 29126416; PMCID: PMC5681758. 6: Newton RW. Physostigmine salicylate in the treatment of tricyclic antidepressant overdosage. JAMA. 1975 Mar 3;231(9):941-3. PMID: 1173100. 7: Pinder N, Zimmermann JB, Gastine S, Würthwein G, Hempel G, Bruckner T, Hoppe- Tichy T, Weigand MA, Swoboda S. Continuous infusion of physostigmine in patients with perioperative septic shock: A pharmacokinetic/pharmacodynamic study with population pharmacokinetic modeling. Biomed Pharmacother. 2019 Oct;118:109318. doi: 10.1016/j.biopha.2019.109318. Epub 2019 Aug 6. PMID: 31398669. 8: Perry PJ, Wilding DC, Juhl RP. Anticholinergic psychosis. Am J Hosp Pharm. 1978 Jun;35(6):725-8. PMID: 665688. 9: Bolourchian N, Hadidi N, Foroutan SM, Shafaghi B. Development and optimization of a sublingual tablet formulation for physostigmine salicylate. Acta Pharm. 2009 Sep;59(3):301-12. doi: 10.2478/v10007-009-0028-5. PMID: 19819826. 10: Davis KL, Berger PA, Hollister LE, Defraites E. Physostigmine in mania. Arch Gen Psychiatry. 1978 Jan;35(1):119-22. doi: 10.1001/archpsyc.1978.01770250121012. PMID: 339869.